Insights Into Differentiated Thyroid Cancer (DTC) 2024

Perspectives on ​the management of radioactive iodine (RAI)-refractory or -ineligible metastatic DTC and second-line systemic therapy

Southeast – April 29, 2024
Purchase Report

Faculty Chair

Marcia Brose, MD, PhD

Sidney Kimmel Cancer Center, Philadelphia, PA, USA

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Management of RAI-Refractory or -Ineligible Metastatic DTC
  • Second-Line Systemic Therapy

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and in-depth moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in Insights Into Differentiated Thyroid Cancer (DTC) 2024.

Complete the form below to receive additional information.